Immunotech Laboratories (IMMB) Patented "IPF" Technology A Serious
Contender In The Race For HIV & Cancer Cures
PASADENA, Calif., Feb. 4, 2013 /PRNewswire/ --
CSNNewswire/Immunotech Laboratories, Inc. (PINKSHEETS:IMMB)
Company Director Mr. Bo. Linton of Immunotech Laboratories, Inc,
a Pasadena California based
publicly traded company with patented "IPF" Technology today
stated Immunotech's technology is now considered a major
contender in the race for HIV & Cancer cures. Recent
information provided by the company for clinical testing results in
both the HIV and Cancer sectors for terminal (Salvage) patients
showed the use of the company's patented "IPF" vaccine treatments
significantly reduced the number of infected cells while leaving
the non infected cells in tact, and almost immediately started the
regeneration of the body's natural immune system.
Mr. Linton further commented the company recently received an
initial inquiry for a significant order of the company's patented
HIV vaccine by an International associate for use as an
"Experimental Drug". If confirmed the initial order would be
in excess of several Million Dollars. This would expand the
company's operations from Research & Development to a
Bio-Pharma manufacturing company. In Africa, where approved
experimental treatments are permitted, there are approximately 30
Million HIV/AIDS patients alone.
About Immunotech Laboratories
Immunotech Laboratories is a drug development company committed
to the commercialization of its proprietary proteins for the
treatment of debilitating infectious diseases such as HIV, Cancer,
Hepatitis and AIDS. Immunotech is committed to creating drugs for
the better health of mankind. Please visit Immunotechlab.com
for information regarding the companies patented treatments,
valuations and goals.
Safe Harbor Statement: This news release contains
forward-looking statements that involve risks and uncertainties
associated with financial projections, budgets, milestone
timelines, clinical development, regulatory approvals, and other
risks described by Immunotech Laboratories, Inc. from time to time
in its periodic reports filed with the SEC. IPF is not approved by
the US Food and Drug Administration or by any comparable regulatory
agencies elsewhere in the world. While Immunotech Laboratories
believes that the forward-looking statements and underlying
assumptions contained therein are reasonable, any of the
assumptions could be inaccurate, including, but not limited to, the
ability of Immunotech Laboratories to establish the efficacy of IPF
in the treatment of any disease or health condition, the
development of studies and strategies leading to commercialization
of IPF in the United States, the
obtaining of funding required to carry out the development plan,
the completion of studies and tests on time or at all, and the
successful outcome of such studies or tests. Therefore, there can
be no assurance that the forward-looking statements included in
this release will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included
herein, Immunotech Laboratories or any other person that the
objectives and plans of Immunotech Laboratories will be achieved
should not regard the forward-looking statements as a
representation.
Immunotech Contact
ir@immunotechlab.com
Investor Relations:
The Nabors Group: 713-875-9200
E-mail: naborsgroup@yahoo.com
www.facebook.com/Naborsgroup
SOURCE Immunotech Laboratories, Inc.